CECCON, MONICA

CECCON, MONICA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 26 (tempo di esecuzione: 0.029 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 02 - Intervento a convegno 2009 PIAZZA, ROCCO GIOVANNIREDAELLI, SARACECCON, MONICAMOLOGNI, LUCAPOGLIANI, ENRICO MARIAGAMBACORTI PASSERINI, CARLO +
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 01 - Articolo su rivista 2010 MOLOGNI, LUCACECCON, MONICAPURGANTE, STEFANIAMAGISTRONI, VERAGAMBACORTI PASSERINI, CARLO +
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 01 - Articolo su rivista 2012 MOLOGNI, LUCACECCON, MONICAGAMBACORTI PASSERINI, CARLO +
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 01 - Articolo su rivista 2012 REDAELLI, SARAMOLOGNI, LUCAROSTAGNO, ROBERTAPIAZZA, ROCCO GIOVANNIMAGISTRONI, VERACECCON, MONICAVILTADI, MICHELAGAMBACORTI PASSERINI, CARLO +
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 01 - Articolo su rivista 2013 CECCON, MONICAMOLOGNI, LUCAGAMBACORTI PASSERINI, CARLO +
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 07 - Tesi di dottorato Bicocca post 2009 2013 CECCON, MONICA
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 02 - Intervento a convegno 2014 REDAELLI, SARAPERINI, PIETROCECCON, MONICAPIAZZA, ROCCO GIOVANNIRIGOLIO, ROBERTAGAMBACORTI PASSERINI, CARLO +
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 02 - Intervento a convegno 2014 Ceccon, MMologni, LPiazza, RPirola, AFontana, DGambacorti-Passerini, C +
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 01 - Articolo su rivista 2014 GAMBACORTI PASSERINI, CARLOREDAELLI, SARACECCON, MONICAMOLOGNI, LUCAMESSA, MARIA CRISTINAGuerra, LANTOLINI, LAURAPIAZZA, ROCCO GIOVANNI +
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 01 - Articolo su rivista 2015 FONTANA, DILETTACECCON, MONICAGAMBACORTI PASSERINI, CARLOMOLOGNI, LUCA
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 99 - Altro 2015 Ceccon M.Mologni L.Piazza R.Pirola A.Fontana D. +
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 01 - Articolo su rivista 2015 CECCON, MONICAMOLOGNI, LUCAPIAZZA, ROCCO GIOVANNIPIROLA, ALESSANDRAFONTANA, DILETTAGAMBACORTI PASSERINI, CARLO +
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 02 - Intervento a convegno 2015 Redaelli, SCeccon, MPirola, APeronaci, MGambacorti-Passerini, CMologni, L
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 02 - Intervento a convegno 2015 Mologni, LCeccon, MFontana, DPirola, APiazza, RGambacorti-Passerini, C
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 02 - Intervento a convegno 2015 Ceccon, MMologni, LBombelli, SRigolio, RCASATI, COSTANZAGambacorti Passerini, C +
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 01 - Articolo su rivista 2015 MOLOGNI, LUCACECCON, MONICAPIROLA, ALESSANDRAPIAZZA, ROCCO GIOVANNIGAMBACORTI PASSERINI, CARLO +
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 01 - Articolo su rivista 2015 CECCON, MONICAGAMBACORTI PASSERINI, CARLO +
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 01 - Articolo su rivista 2015 REDAELLI, SARAPERINI, PIETROCECCON, MONICAPIAZZA, ROCCO GIOVANNIRIGOLIO, ROBERTAMAURI, MARIOGAMBACORTI PASSERINI, CARLO +
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 01 - Articolo su rivista 2016 REDAELLI, SARACECCON, MONICAANTOLINI, LAURARIGOLIO, ROBERTAPIROLA, ALESSANDRAPERONACI, MARCOGAMBACORTI PASSERINI, CARLOMOLOGNI, LUCA
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 01 - Articolo su rivista 2016 CECCON, MONICAMOLOGNI, LUCABOMBELLI, SILVIARIGOLIO, ROBERTACASATI, COSTANZAMASTINI, CRISTINAGAMBACORTI PASSERINI, CARLO +